Cy5.5
Cat.No:IC8650 Solarbio
CAS:210892-23-2(Free base)
Molecular Formula:C41H44N2O14S4
Molecular Weight:917.05
Storage:Powder:-20℃,1 year;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year(protect from light)
Purity:≥96%
Appearance:Soild
Qty:
Size:
{{cart_num}}
My CartCAS:210892-23-2(Free base)
Molecular Formula:C41H44N2O14S4
Molecular Weight:917.05
Storage:Powder:-20℃,1 year;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year(protect from light)
Purity:≥96%
Appearance:Soild
Qty:
Size:
| CAS | 210892-23-2(Free base) |
| Name | Cy5.5 |
| Molecular Formula | C41H44N2O14S4 |
| Molecular Weight | 917.05 |
| Solubility | Soluble in DMSO ≥10mg/mL(Need ultrasonic) |
| Purity | ≥96% |
| Appearance | Soild |
| Storage | Powder:-20℃,1 year;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year(protect from light) |
| MDL | MFCD31560494 |
| SMILES | CCN1C2=C(C3=C(C=C2)C(=CC(=C3)S(=O)(=O)O)S(=O)(=O)[O-])C(C1=CC=CC=CC4=[N+](C5=C(C4(C)C)C6=C(C=C5)C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)CCCCCC(=O)O)(C)C |
| InChIKey | LIZDKDDCWIEQIN-UHFFFAOYSA-N |
| InChI | InChI=1S/C41H44N2O14S4/c1-6-42-31-18-16-27-29(21-25(58(46,47)48)23-33(27)60(52,53)54)38(31)40(2,3)35(42)13-9-7-10-14-36-41(4,5)39-30-22-26(59(49,50)51)24-34(61(55,56)57)28(30)17-19-32(39)43(36)20-12-8-11-15-37(44)45/h7,9-10,13-14,16-19,21-24H,6,8,11-12,15,20H2,1-5H3,(H4-,44,45,46,47,48,49,50,51,52,53,54,55,56,57) |
| PubChem CID | 131875897 |
| Background | Cy5.5, a CY dye, is a near-infrared fluorescent dye that is in the red/near-infrared interface. Ex/Em(nm)=680/710. |
| Unit | Bottle |
| Specification | 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer
Click to check >>Author:Li Bozhao, Qi Feilong, Zhu Fei, Lu Zefang, Wang Meiqi, Chu Tianjiao, Wu Suying, Wei Jingyan, Song Zhenchuan, Sukumar Saraswati, Zhang Cheng, Xu Jiangfei, Li Suping, Nie Guangjun
IF:11.2000
Publish_to:CANCER RESEARCH
PMID:37326467
Manual Download